Whalesbook
Dishman Carbogen Amcis FY26 Results Show Strong Profit and Revenue Gains
Annual Profit After Tax (PAT): ₹97.4 crores
Annual Revenue: ₹2,932 crores
Key Investor Note: The company achieved a strong profit rebound and revenue growth, though losses from its French subsidiary and high Indian debt remain areas to monitor.
What Happened
Dishman Carbogen Amcis announced its financial results for the fiscal year ending March 31, 2026. Net profit jumped to ₹97.4 crores, a significant leap from ₹3.2 crores in the previous year. Annual revenue increased to ₹2,932 crores, up from ₹2,711 crores in FY25. The company also reported higher EBITDA of ₹565 crores, with EBITDA margins improving to 19.3% from 17.3% in FY25, indicating enhanced operational efficiency.
Why This Matters
This substantial improvement in profitability and revenue growth points to a positive trend for Dishman Carbogen Amcis. The better EBITDA margins suggest effective operational management. These results are important for investors evaluating the company's financial standing and future growth potential, especially its capacity to manage its debt obligations and revitalize underperforming segments.
Company Background
Dishman Carbogen Amcis operates within the Contract Development and Manufacturing Organization (CDMO) and Marketable Molecules sectors. The company has been actively working to reduce its debt burden and boost operational performance. The fiscal year 2026 results represent a significant turnaround from the much lower profit reported in FY25.
What's Next for the Company
The improved financial performance could enhance investor confidence. Dishman Carbogen Amcis's focus on reducing long-term debt and enhancing operations, including its integrated drug substance and drug product offerings, may strengthen its market position. A key recent development is the Board's approval to refinance high-cost debt within the Indian parent entity.
Potential Risks
Despite the strong overall results, the company faces challenges. Its French subsidiary recorded an EBITDA loss of EUR 9 million in FY26. The Indian entity continues to service substantial high-interest debt, totaling approximately ₹800 crores at rates of 10.5-11%. Additionally, risks from foreign currency fluctuations and broader geopolitical uncertainties persist.
Key Metrics
- Marketable Molecules Revenue: Increased to INR 490.65 crores in FY26 from INR 418.5 crores in FY25.
- Net Debt: Decreased to 146.8 CHF million as of March 31, 2026, from 157.6 CHF million.
- France Subsidiary Outlook: Targeting revenue of EUR 11-12 million for FY27.
What to Monitor
Investors will be closely observing the turnaround efforts at the France subsidiary, the progress of the debt refinancing plans in India, and the company's advancement towards its long-term financial targets. These targets include achieving a 25% EBITDA margin by FY28 and a 15% revenue compound annual growth rate (CAGR).